PPMI Study Annual Meeting
Team members (from left to right) Ray James, Dr. Marie Saint-Hilaire, Amber Payne, Abigail Desrosiers, and Dr. Katelyn Bird attended the PPMI Study Annual Meeting in New York City from May 4–6, 2026.
PPMI sites span across the United States, Canada, Europe, the Middle East, and Africa. As of May 5, 2026, there are 4,649 participants enrolled in PPMI Clinical, including individuals with Parkinson’s disease, individuals at risk, and healthy controls.
If you are participating in the PPMI Study, be sure to sign up for myPPMI, where you can track your personal study journey, view research updates, join new study opportunities, and contribute data to help accelerate Parkinson’s research.
Topics discussed at the meeting included imaging, biologics, cognition and neurobehavior, sleep, and many other areas of ongoing research.
One major update shared at the meeting was that the study name has officially changed from the “Parkinson’s Progression Markers Initiative” to the “Parkinson’s Precision Medicine Initiative.” This new name reflects the study’s evolution from solely tracking disease progression to actively advancing more personalized and targeted treatments for Parkinson’s disease.
The BUMC Movement Disorders team was honored with several site award recognitions during the meeting.